Izotropic Provides Marketing Update
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 13, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into an agreement with 1822053 Alberta Ltd. (d/b/a Evolux Capital) ("Evolux") to provide marketing services to the Company. The services are expected to include the creation and distribution...
2025-06-13 8:00 AM EDT
Izotropic Revises License Agreement with The Regents of the University of California
- License agreement enables U.S. FDA approval or foreign equivalent (CE mark) -- Amendment aligns with Company's timelines for IzoView product launch -- Agreement amendment fees of USD $85K payable in installments -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is...
2025-06-10 8:00 AM EDT
FDA-Zulassungsverfahren von Izotropic genehmigt - Unternehmen gibt Update
- Die Übereinstimmung mit den Vorgaben der FDA wurde bestätigt. Der Weg zu der wichtigen klinischen Studie in den USA ist somit frei -- 150-seitiger strategischer Geschäftsplan und genaue Finanzmodelle fertiggestellt -- Kontaktaufnahme mit Investoren zur Finanzierung der klinischen Durchführung und des Markteintritts im Gange -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - Dienstag, 20. Mai 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" oder das "Unternehmen") ist ein Anbieter medizintechnischer bildgebender Systeme, der innovative und
2025-05-20 3:48 PM EDT
Izotropic's U.S. FDA Regulatory Pathway Greenlit, Company Provides Corporate Update
- Regulatory alignment with FDA confirmed, clearing path to pivotal U.S. clinical trial -- 150-page strategic business plan and advanced financial models completed -- Investor outreach launched to fund clinical execution and market entry -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - May 16, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast...
2025-05-16 10:36 PM EDT
Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - April 2, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has engaged an International Communications Consultant, and granted Incentive Stock Options and Restricted Share Units to Directors, Advisors, and Key Consultants. International Communications ConsultantIzotropic has engaged JG Global Communications, led...
2025-04-02 3:30 PM EDT
Izotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening Indication
- FDA meeting facilitated positive collaborative exchange -- Key topics included the clinical study protocol synopsis, the benefits versus risks of contrast-enhancement, and the management of breast cancers found on IzoView Breast CT that are not visible on digital breast tomosynthesis -- Izotropic to submit meeting minutes to the FDA prior to more detailed disclosure -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - March 25, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a...
2025-03-25 8:00 AM EDT
Izotropic to Present at Investor Conference March 13th
- CEO to discuss IzoView's competitive advantage, expansion strategy, and potential revenue models -- Event includes live Q and A, attendance is complimentary -- Individual and institutional investors, advisors, and analysts welcome -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - March 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is...
2025-03-10 8:00 AM EDT
FDA Sets Meeting Date with Izotropic
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 19, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that the U.S. Food and Drug Administration ("FDA") has set the Company's pre-submission meeting date, further to its January pre-submission filing. The Company filed a pre-submission with the FDA on the...
2025-02-19 8:00 AM EST
Izotropic Closes Non-Brokered Private Placement
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 14, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its February 7th announcement it has completed a non-brokered private placement financing (the "Offering"), whereby the Company issued 3,033,333 units (each, a "Unit") at a price of $0.15 per...
2025-02-14 8:00 AM EST
Izotropic Announces Non-Brokered Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 7, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announced today that it intends to complete a small non-brokered private placement financing (the "Offering") of up...
2025-02-07 9:00 AM EST
Izotropic Reschedules Investor Conference Presentation to March 13th
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 5, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces it is rescheduling its attendance and presentation at the OTC's Virtual Investor Conference from Thursday February 6th to Thursday March 13th, 2025. Due to a family emergency, the CEO is no longer...
2025-02-05 8:31 PM EST
Izotropic to Present at Investor Conference February 6th
- CEO to present overview of Company value proposition, unique catalysts, and near-term objectives -- Event includes live Q and A, attendance is complimentary -- Individual and institutional investors, advisors, and analysts welcome -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 3, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers,...
2025-02-03 8:00 AM EST
Izotropic Announces Timelines and Milestones to IzoView Product Launch
- Unique dense breast tissue focus to drive expedited recruitment rates; modular clinical study design reduces time to PMA submission by ~6 months -- 3 Site U.S.-based clinical study enables early data collection to kickstart European CE Mark Application -- Company to announce development of 2 new medical imaging devices in the next 12 months to trigger momentum and increase valuation during clinical data collection phase -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - January 29, 2025) - Izotropic Corporation...
2025-01-29 8:00 AM EST
Izotropic Featured in Announcement of Research and Markets' U.S. Breast Cancer Analysis and Forecast
- Company listed in Research and Markets' announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - "U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-20301"--Report supports Company's regulatory strategy for IzoView Breast CT, reinforces high demand for new breast imaging modalities, strengthens the potential...
2025-01-17 8:00 AM EST
Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions
-New FDA Consultant is the former Director of the Division of Imaging, Diagnostics, and Software Reliability at the U.S Food and Drug Administration--New Biostatistical Consultant is the former Deputy Director of the Biostatistics and Data Management Center of the American College of Radiology Imaging Network, an NIH-funded cooperative that conducts clinical trials to evaluate the use of diagnostic imaging and image-guided treatments for cancer, has decades of successful experience in design and analysis of clinical studies of medical imaging devices...
2025-01-15 8:00 AM EST
Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening
-A screening indication for women with dense breast tissue adjunctive to 3D mammography increases the market size for annual IzoView scans by over 800%1 for initial approval and product launch- -Regulatory strategy responds to the "urgent call2" from the U.S. Preventative Services Task Force for solutions to finding breast cancers earlier in women with dense breast tissue--Comprehensive filing includes patient acquisition and clinical study plans that validate a projected clinical study timeline of 2.5 years with an approximate cost of USD...
2025-01-09 8:00 AM EST
Izotropic Provides Update on Annual General Meeting Materials and Voting Procedures
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announces that due to the suspension of mail service in Canada due to the nationwide strike of the Canadian Union of Postal Workers, that the notice of meeting, information circular, requests for financial statements and proxy form (the "Meeting Materials") for the Company's upcoming Annual General...
2024-12-04 2:43 PM EST
Izotropic Announces Regulatory Approval Plans to Launch Izoview for Breast Cancer Diagnostics in Patients with Dense Breasts in the U.S. and EU
Vancouver, British Columbia--(Newsfile Corp. - August 23, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a breast CT (computed tomography) imaging system, is pleased to announce that it is pursuing a regulatory strategy in the U.S. and EU to launch IzoView as a diagnostic device indicated for use in patients with dense breast tissue, a normal variation associated with an increased risk for developing breast cancers.The Company's reformed regulatory strategy positions IzoView...
2024-08-23 9:00 AM EDT
Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") - Further to the Company's news release of June 6, 2024, the Company is pleased to announce that it has completed the first tranche of its non-brokered private placement financing (the "Offering"), whereby the Company issued 1,800,000 units (each, a "Unit") at a price of $0.10 per Unit for gross proceeds of $180,000.00. Each Unit consists of one...
2024-06-14 9:00 AM EDT
Izotropic Corporation Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announced today that it intends to complete a small non-brokered private placement financing (the "Offering") of up to 3,000,000 units of the Company, (each a "Unit") at a price of $0.10 per each Unit for a gross proceeds of up to $300,000.00. Each Unit will consist of one...
2024-06-06 9:00 AM EDT